|
Market Closed -
Other stock markets
|
After hours 04:00:00 | |||
| 101.96 USD | +1.47% |
|
99.84 | -2.07% |
| 06-13 | Cigna's Express Scripts sues to block pharmacy ownership law in Tennessee | RE |
| 06-10 | CVS Will Pay $36.5 Million to Settle Insulin Fraud Claims With State AGs, DOJ | DJ |
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Revenues | 291B | 322B | 357B | 371B | 400B | |||||
Total Revenues | 291B | 322B | 357B | 371B | 400B | |||||
Cost of Goods Sold, Total | 240B | 268B | 303B | 321B | 347B | |||||
Gross Profit | 50.85B | 53.46B | 53.28B | 49.25B | 53.13B | |||||
Selling General & Admin Expenses, Total | 37.07B | 38.04B | 39.2B | 41.23B | 43.11B | |||||
Other Operating Expenses, Total | 37.07B | 38.04B | 39.2B | 41.23B | 43.11B | |||||
Operating Income | 13.78B | 15.42B | 14.07B | 8.02B | 10.02B | |||||
Interest Expense, Total | -2.5B | -2.29B | -2.66B | -2.96B | -3.12B | |||||
Interest And Investment Income | 1.2B | 838M | 1.15B | 2.15B | 2.23B | |||||
Net Interest Expenses | -1.3B | -1.45B | -1.5B | -805M | -886M | |||||
Other Non Operating Income (Expenses) | -4M | -4M | -6M | -5M | -5M | |||||
EBT, Excl. Unusual Items | 12.47B | 13.96B | 12.56B | 7.21B | 9.13B | |||||
Restructuring Charges | -1.36B | - | -553M | -1.21B | -93M | |||||
Merger & Related Restructuring Charges | -132M | - | -487M | -243M | -117M | |||||
Impairment of Goodwill | -431M | - | - | - | -5.72B | |||||
Gain (Loss) On Sale Of Assets | - | -2.53B | -349M | - | 483M | |||||
Asset Writedown | - | - | - | - | - | |||||
Legal Settlements | 263M | -5.8B | - | -100M | -1.54B | |||||
Other Unusual Items | -391M | - | - | 491M | - | |||||
EBT, Incl. Unusual Items | 10.42B | 5.63B | 11.17B | 6.15B | 2.14B | |||||
Income Tax Expense | 2.52B | 1.46B | 2.8B | 1.56B | 408M | |||||
Earnings From Continuing Operations | 7.9B | 4.16B | 8.37B | 4.59B | 1.73B | |||||
Earnings Of Discontinued Operations | - | - | - | - | - | |||||
Net Income to Company | 7.9B | 4.16B | 8.37B | 4.59B | 1.73B | |||||
Minority Interest | 12M | -16M | -24M | 28M | 40M | |||||
Net Income - (IS) | 7.91B | 4.15B | 8.34B | 4.61B | 1.77B | |||||
Preferred Dividend and Other Adjustments | - | - | - | - | - | |||||
Net Income to Common Incl Extra Items | 7.91B | 4.15B | 8.34B | 4.61B | 1.77B | |||||
Net Income to Common Excl. Extra Items | 7.91B | 4.15B | 8.34B | 4.61B | 1.77B | |||||
Per Share Items | ||||||||||
Net EPS - Basic | 6 | 3.16 | 6.49 | 3.66 | 1.4 | |||||
Basic EPS - Continuing Operations | 6 | 3.16 | 6.49 | 3.66 | 1.4 | |||||
Basic Weighted Average Shares Outstanding | 1.32B | 1.31B | 1.28B | 1.26B | 1.27B | |||||
Net EPS - Diluted | 5.95 | 3.14 | 6.47 | 3.66 | 1.39 | |||||
Diluted EPS - Continuing Operations | 5.95 | 3.14 | 6.47 | 3.66 | 1.39 | |||||
Diluted Weighted Average Shares Outstanding | 1.33B | 1.32B | 1.29B | 1.26B | 1.27B | |||||
Normalized Basic EPS | 5.92 | 6.64 | 6.09 | 3.6 | 4.53 | |||||
Normalized Diluted EPS | 5.87 | 6.58 | 6.07 | 3.59 | 4.52 | |||||
Dividend Per Share | 2 | 2.2 | 2.42 | 2.66 | 2.66 | |||||
Payout Ratio | 33.19 | 70.06 | 37.54 | 73.1 | 192.14 | |||||
American Depositary Receipts Ratio (ADR) | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | |||||
Supplemental Items | ||||||||||
EBITDA | 18.29B | 19.66B | 18.44B | 12.62B | 14.62B | |||||
EBITA | 16.04B | 17.22B | 15.98B | 10.04B | 12B | |||||
EBIT | 13.78B | 15.42B | 14.07B | 8.02B | 10.02B | |||||
EBITDAR | 21.5B | 22.82B | 21.56B | 15.64B | 17.64B | |||||
Total Revenues (As Reported) | 292B | 322B | 358B | 373B | 402B | |||||
Effective Tax Rate - (Ratio) | 24.2 | 26 | 25.11 | 25.41 | 19.1 | |||||
Current Domestic Taxes | 2.95B | 3.54B | 3.48B | 2.13B | 192M | |||||
Current Foreign Taxes | - | - | - | - | 114M | |||||
Total Current Taxes | 2.95B | 3.54B | 3.48B | 2.13B | 306M | |||||
Deferred Domestic Taxes | -428M | -2.08B | -676M | -572M | 102M | |||||
Total Deferred Taxes | -428M | -2.08B | -676M | -572M | 102M | |||||
Normalized Net Income | 7.81B | 8.71B | 7.83B | 4.53B | 5.74B | |||||
Interest Capitalized | - | - | - | - | - | |||||
Interest on Long-Term Debt | 2.54B | 2.29B | 73M | 71M | 69M | |||||
Non-Cash Pension Expense | -186M | -173M | -94M | -104M | -117M | |||||
Supplemental Operating Expense Items | ||||||||||
Advertising Expense | 523M | 745M | 985M | 989M | 970M | |||||
Selling and Marketing Expenses | 523M | 745M | 985M | 989M | 970M | |||||
Net Rental Expense, Total | 3.21B | 3.16B | 3.13B | 3.02B | 3.02B | |||||
Imputed Operating Lease Interest Expense | 798M | 787M | 886M | 882M | 924M | |||||
Imputed Operating Lease Depreciation | 2.41B | 2.37B | 2.24B | 2.14B | 2.09B | |||||
Stock-Based Comp., Other (Total) | 484M | 447M | 588M | 540M | 535M | |||||
Total Stock-Based Compensation | 484M | 447M | 588M | 540M | 535M |
- Stock Market
- Stocks
- CVS Stock
- Financials CVS Health Corporation
- Income Statement
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition















